Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncology Aids Pfizer As Biosimilars Track To $1bn In 2020

Upjohn Separation In Progress Ahead Of Mylan Merger

Executive Summary

Pfizer is on course for a major milestone for biosimilars this year, as it continues to make plans for the separation of its off-patent and mature brands unit, Upjohn, ahead of its merger with Mylan.

You may also be interested in...



A Year Of Surprises Shakes Up Industry Top 10

In an eventful year for the off-patent industry, the world’s leading generics and biosimilars players have switched places in Generics Bulletin’s newly-compiled global sales ranking.

Updated: Multiple Biosimilars To Avastin Have Launched In EU

Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.

Mylan Shareholders Say Yes To Upjohn Merger

Mylan and Upjohn are aiming to combine into Viatris by the end of 2020, together ticking off regulatory and financial milestones since the deal was announced in late July last year. Mylan shareholder approval remained a condition for the deal to close – with a previous vote delayed by more than two months due to the COVID-19 pandemic.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB150113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel